Regulatory expectations in genomics-driven drug development are evolving alongside scientific practice, clinical implementation, and policy. While formal guidan...
Continue reading
At Sano, every product, pipeline, and participant experience depends on secure, reliable, and scalable infrastructure. That foundation is shaped by our platform...
Continue reading
At the recent Evolution of the Cell and Gene Therapy (CGT) Sector Workshop by the Alliance for Regenerative Medicine (ARM), speakers from across industry, acade...
Continue reading
AI is becoming a core component of drug development and clinical research. Models are improving and regulatory frameworks are evolving, but progress still depen...
Continue reading
As part of new efforts to improve FDA processes and enhance communication with stakeholders, they hosted a roundtable on cell and gene therapy on June 5th, 2025...
Continue reading
In May and June of 2025, the Food and Drug Administration (FDA) announced a series of developments related to the use of artificial intelligence (AI) across its...
Continue reading
Precision medicine has the potential to transform how we understand and treat autoimmune and inflammatory diseases, but only if we can align innovation with inf...
Continue reading
Autoimmune diseases include more than 80 conditions defined by immune system dysfunction in which the body mistakenly attacks healthy tissue. Treating autoimmun...
Continue reading
In the latest episode of The Genetics Podcast, host and Sano Genetics CEO Patrick Short welcomes Dr. Eric Green, CEO and Founder of Trace Neuroscience. Eric has...
Continue reading
As of March 2023, 3,900 gene therapy trials were noted as ongoing, completed, or approved across 46 different countries. An analysis of the second quarter of 20...
Continue reading